R&G PharmaStudies Co. Ltd. A Cash Flow Conversion Efficiency
R&G PharmaStudies Co. Ltd. A cash flow conversion efficiency. Based on the latest financial reports, R&G PharmaStudies Co. Ltd. A (301333) has a cash flow conversion efficiency ratio of 0.090x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥40.98 Million ≈ $6.00 Million USD) by net assets (CN¥454.13 Million ≈ $66.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of R&G PharmaStudies Co. Ltd. A (2019–2025)
Cash flow conversion efficiency of R&G PharmaStudies Co. Ltd. A from 2019 to 2025. This chart illustrates how R&G PharmaStudies Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View R&G PharmaStudies Co. Ltd. A share price for real-time trading data and today's change.
R&G PharmaStudies Co. Ltd. A Cash Flow Conversion Ratio Explained
R&G PharmaStudies Co. Ltd. A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
R&G PharmaStudies Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of R&G PharmaStudies Co. Ltd. A ranked by their cash flow conversion efficiency. Also see R&G PharmaStudies Co. Ltd. A (301333) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangzhou Pearl River Piano Group Co Ltd
SHE:002678
|
-0.021x |
|
InMode Ltd
NASDAQ:INMD
|
0.033x |
|
United Renewable Energy Co Ltd
TW:3576
|
-0.009x |
|
Huafa Industrial Co Ltd Zhuhai
SHG:600325
|
0.074x |
|
Dharma Satya Nusantara Ptdsn
JK:DSNG
|
0.053x |
|
AIC Inc
TWO:3693
|
-0.079x |
|
Alto Neuroscience, Inc.
NYSE:ANRO
|
-0.076x |
|
Zbit Semiconductor Inc. A
SHG:688416
|
N/A |
Annual Cash Flow Conversion Efficiency for R&G PharmaStudies Co. Ltd. A (2019–2025)
The table below shows the annual cash flow conversion efficiency of R&G PharmaStudies Co. Ltd. A from 2019 to 2025. Review cash generation quality of R&G PharmaStudies Co. Ltd. A to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.98 Billion ≈ $289.11 Million |
CN¥114.20 Million ≈ $16.71 Million |
0.058x | -31.42% |
| 2024-12-31 | CN¥1.84 Billion ≈ $268.68 Million |
CN¥154.76 Million ≈ $22.65 Million |
0.084x | -23.20% |
| 2023-12-31 | CN¥1.75 Billion ≈ $256.76 Million |
CN¥192.56 Million ≈ $28.18 Million |
0.110x | +34.06% |
| 2022-12-31 | CN¥1.59 Billion ≈ $233.21 Million |
CN¥130.47 Million ≈ $19.09 Million |
0.082x | -68.72% |
| 2021-12-31 | CN¥437.81 Million ≈ $64.07 Million |
CN¥114.57 Million ≈ $16.77 Million |
0.262x | +99.97% |
| 2020-12-31 | CN¥336.98 Million ≈ $49.31 Million |
CN¥44.10 Million ≈ $6.45 Million |
0.131x | -68.41% |
| 2019-12-31 | CN¥249.74 Million ≈ $36.55 Million |
CN¥103.48 Million ≈ $15.14 Million |
0.414x | -- |
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology se… Read more